Steven Rosen, MD, accepts Editor-in-Chief position for Oncology News International

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 1
Volume 17
Issue 1

Steven Rosen, MD, Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine, Northwestern University, and director of the Robert H. Lurie Comprehensive Cancer Center, has agreed to accept the position of Editor-in-Chief for Oncology News International (ONI).

Steven Rosen, MD, Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine, Northwestern University, and director of the Robert H. Lurie Comprehensive Cancer Center, has agreed to accept the position of Editor-in-Chief for Oncology News International (ONI).

Dr. Rosen will work closely with Oncology News International's editorial advisory board and staff to help set the editorial tone and direction for the publication.

"I am very proud to follow in the footsteps of my dear friend and mentor Marty Abeloff-a great role model for all oncologists," Dr. Rosen said. "I hope to sustain the high quality of the journal and seek the guidance of our readership to ensure that the most important issues affecting our field are communicated in a timely and scholarly manner."

Dr. Abeloff, who died last year, was director of the Johns Hopkins Kimmel Cancer Center, and served as Editor-in-Chief of ONI from its inception in 1982.

Dr. Rosen has worked with Oncology News International in the past as an editorial advisor and is lead author of the non-Hodgkin's lymphoma chapter of the Cancer Management Handbook, a publication of the group that produces ONI.

"We're extremely pleased to have Dr. Rosen on board as Editor-in-Chief," said John C. Hayes, editorial director. "He brings a level of energy, knowledge, and experience that will be of tremendous value to Oncology News International and its readers."

Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr. Rosen completed his residency in internal medicine at Northwestern and a fellowship in medical oncology at the National Cancer Institute.

Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. He has received numerous grants, awards, and contracts, and has published more than 200 scientific papers.

As director of the Lurie Cancer Center, Dr. Rosen has successfully competed for an NCI Cancer Center Support Grant, NCI grants for his laboratory research, an NCI RAID Contract grant for the development of a novel purine analog, and grants from the Leukemia and Lymphoma Society of America and the American Cancer Society.

Dr. Rosen serves on several editorial boards and is editor of Cancer Treatment & Research. He is a member of all major national associations that focus on oncology and has held leadership positions in the Eastern Cooperative Oncology Group, the American Association of Cancer Institutes, and the National Comprehensive Cancer Network.

He serves on the advisory boards of several NCI-designated cancer centers, the Leukemia and Lymphoma Society of America, the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and the Wendy Will Cancer Research Foundation. He has also served as an advisor to Great Britain's Cancer Research Campaign.

Dr. Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), and the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996), and was recognized by the Women's Board of Northwestern Memorial Hospital for Compassionate Care (1996). He is acknowledged in Best Doctors and Oncologists in America, and Best Doctors in Chicago.

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content